Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,076

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

3,076 results for “multiple studies”

Learn how ShareScore rates datasets ↗
dryad40/100

Data from: A well-studied parasitoid fly of field crickets uses multiple alternative hosts in its introduced range

<p>Organisms and their natural enemies can have dynamic coevolutionary trajectories, but anthropogenic effects like species introductions interrupt existing coevolutionary relationships. For parasites in particular, if they are introduced to a location without their hosts, they can only persist in the new environment if alternative hosts are 1) present, 2) detectable to parasites, and 3) capable of sustaining parasites. The circumstances surrounding the addition of alternative hosts to a parasite's repertoire are rarely observed. The parasitoid fly Ormia ochracea locates its field cricket hosts by orienting acoustically to their conspicuous mating songs. In Hawaii, O. ochracea is only known to parasitize one species, Teleogryllus oceanicus, but rapid evolution of T. oceanicus mating song over the past 20 years has led to several prevalent morphs of the cricket that produce no song or novel songs that the flies cannot detect. Yet flies persist in populations that lack ancestral singing T. oceanicus, prompting us to investigate the possibility of alternative hosts in Hawaii. We demonstrate first that three potential alternative hosts (Gryllodes sigillatus, Gryllus bimaculatus, and Modicogryllus pacificus) are present. Second, O. ochracea exhibits a positive phonotactic response to all three species' songs in the field and in the lab. And third, O. ochracea can successfully develop to pupae and emerge as adults in all three species. Our discovery of alternative hosts for O. ochracea in Hawaii infuses the system with intriguing complexity and offers extensive opportunities for future work.</p>

opencc-zeroDec 2022View details →
zenodo40/100

Rename Chains: An Exploratory Study on the Occurrence and Characteristics of Identifiers Undergoing Multiple Renamings

<p>This is the dataset that accompanies the study: &quot;<strong>Rename Chains: An Exploratory Study on the Occurrence and Characteristics of Identifiers Undergoing Multiple Renamings</strong>.&quot; This study has been accepted for publication at the 2022 International Workshop on Refactoring.</p> <p><strong><em>Following is the abstract of the study:</em></strong></p> <p>Identifier names play a significant role in program comprehension activities, with high-quality names improving developer productivity and system quality. To correct poor-quality names, developers rename identifiers to reflect their intended purpose better. However, renames do not always result in high-quality, long-lasting names; in many cases, developers perform multiple rename operations on the same identifier throughout the system&#39;s lifetime. In this paper, we report on a large-scale empirical study that examines the occurrence of identifiers undergoing multiple renames (i.e., rename chains). Our findings show the presence of rename chains in almost every project, with methods typically having more rename chains than other identifier types. Furthermore, it is usually the same developer responsible for creating all renames within a chain, with most names maintaining the same grammatical structure. Understanding rename chains can help us provide stronger advice, and targeted research, on how to craft high-quality, long-lasting identifiers.</p>

opencc-by-4.0Feb 2023View details →
ClinicalTrials.gov40/100

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

ClinicalTrials.gov study NCT02312258. IPD Sharing: YES. Countries: 35. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

ClinicalTrials.gov study NCT04667117. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

ClinicalTrials.gov study NCT03889639. IPD Sharing: YES. Countries: 10. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT02290431. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT03215030. IPD Sharing: YES. Countries: 16. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

ClinicalTrials.gov study NCT02990338. IPD Sharing: YES. Countries: 24. Publications: 8.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

ClinicalTrials.gov study NCT01877382. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

ClinicalTrials.gov study NCT03439293. IPD Sharing: YES. Countries: 6. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

ClinicalTrials.gov study NCT02917941. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Inject

ClinicalTrials.gov study NCT03416374. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

ClinicalTrials.gov study NCT02761187. IPD Sharing: YES. Countries: 15. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

ClinicalTrials.gov study NCT02812706. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

ClinicalTrials.gov study NCT04410978. IPD Sharing: YES. Countries: 24. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

ClinicalTrials.gov study NCT02660359. IPD Sharing: YES. Countries: 16. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

ClinicalTrials.gov study NCT02975349. IPD Sharing: YES. Countries: 8. Publications: 6.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

ClinicalTrials.gov study NCT03275285. IPD Sharing: YES. Countries: 16. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

ClinicalTrials.gov study NCT04411641. IPD Sharing: YES. Countries: 31. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

ClinicalTrials.gov study NCT03505099. IPD Sharing: YES. Countries: 6. Publications: 3.

controlledIPD-YESFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record